The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM
Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Jun 25, 2025
Trial Information
Current as of July 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called posterior arteriovenous malformations (pAVMs), which are abnormal connections between arteries and veins in the brain. These can sometimes cause balloon-like bulges in blood vessels called aneurysms, which may burst and cause bleeding in the brain. The study is focused on understanding what factors increase the risk of these specific aneurysms related to blood flow breaking open, which can lead to serious brain bleeding and long-term health problems.
People who might be eligible for this study are those diagnosed with pAVMs that have these flow-related aneurysms, confirmed by special imaging tests, and who have had bleeding in the brain confirmed by a CT scan. Participants should not have a history of stroke or certain other medical conditions like Marfan syndrome or polycystic kidney disease. If you join the study, doctors will collect information about your condition to help identify what increases the chance of aneurysm rupture. This research aims to improve understanding and treatment to better protect patients from dangerous brain bleeds in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. pAVM with flow-related aneurysms were identified by DSA, and subarachnoid hemorrhage was confirmed by CT
- • 2. No history of stroke, Marfan syndrome, polycystic kidney disease
- Exclusion Criteria:
- • 1. pAVM without flow-related aneurysms
- • 2. Absence of clinical data
About The First Affiliated Hospital With Nanjing Medical University
The First Affiliated Hospital of Nanjing Medical University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to implementing rigorous scientific methodologies to evaluate new therapies and treatment approaches. With a multidisciplinary team of experienced healthcare professionals and researchers, the hospital fosters a collaborative environment aimed at enhancing patient outcomes and contributing to the global medical community. Its strategic focus on translational medicine ensures that groundbreaking discoveries are efficiently translated into practical applications for patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Nanjing, Jiangsu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported